I work in the medical and healthcare field so my focus is mainly on Biotech stocks. I try to find the next Celgene, the next Pharamcylics if possible. Been a trader and investor for 13 years. Love the game, and I hope you enjoy my articles on here. Good luck with your investments and I look forward to all of your comments and suggestions. Read more here http://seekingalpha.com/author/carl-cachia/articles
Taylor Dart is a top contributor on Seeking Alpha in both the long ideas and basic materials section of the website. He has over 10 years of experience in active investing and currently holds a top #100 ranking on TipRanks.com for investment performance out of over 5,200 financial bloggers. Taylor has over 10 years of active investing in individual stocks with a compound annual growth rate of 15 percent per year. His main focus is on undervalued growth stocks outperforming the market and their peers. In addition he use extensive technical analysis to capture maximum upside price action, as his belief is that timing is everything. Taylor scans upwards of 1200 stocks nightly on the U.S. and Canadian markets to identify the best fundamental opportunities with the most timely technical setups. He is a huge proponent of trend following and the "Turtles" who enjoyed compound annual growth rates of over 80 percent per year.
"If there is a sudden range expansion in a market that has been trading narrowly, human nature is to try and fade that price move. When you get a range expansion, the market is sending you a very loud, clear signal that the market is getting ready to move in the direction of that expansion.” - Paul Tudor Jones
"While a fundamental analyst may be able to properly evaluate the economics underlying a stock, I do not believe they can predict how the masses will process this same information. Ultimately, it is the dollar-weighted collective opinion of all market participants that determines whether a stock goes up or down. This consensus is revealed by analyzing price."
Mark Abraham , Quantitative Capital Management, L.P.
"Profit targets imply a trader can predict the future. Profit targets are profit-limiting. Trend followers stay in the moment of now, avoid prognostication, and let markets run as far as they go. "
Thomas Vician, Jr.
"We can’t always take advantage of a particular period. But in an uncertain world, perhaps the investment philosophy that makes the most sense, if you study the implications carefully, is trend following. Trend following consists of buying high and selling low. For 19 years we have consistently bought high and sold low. If trends were not the underlying nature of markets, our type of trading would have very quickly put us out of business. It wouldn’t take 19 years or even 19 months of buying high and selling low ALL of the time to bankrupt you. But trends are an integral, underlying reality in life. How can someone buy high and sell low and be successful for two decades unless the underlying nature of markets is to trend? On the other hand, I’ve seen year-after-year, brilliant men buying low and selling high for a while successfully and then going broke because they thought they understood why a certain investment instrument had to perform in accordance with their personal logic. "
John W. Henry
I have more than 10 years experience investing in commodities and hard assets such as gold and silver miners, exploration companies, oil and gas producers, MLPs, and various other sectors.
As I'm a long-term investor, I'll highlight some stockpicks which will have a 5-7 year investment horizon. As I strongly believe a portfolio should consist of a mixture of dividend-paying stocks and growth stocks, my articles will reflect my thoughts on this mixture.
I used to run a limited partnership, boutique hedge fund in the 90s. Retired in 2000 and moved from New York City to Toronto, Canada, got married, raised a family and basically settled down. After a few years in Toronto, my wife got tired of the city’s 8 months of cold weather and insisted that we move to a city where there are 8 months of warm and balmy weather. So we settled on San Diego, CA and moved here in 2005 and now call this lovely city with the most perfect weather, home. After moving to Sun Diego, I decided to come out of retirement and start an Internet company that helps non-profits, especially school PTAs, raise money. After a somewhat long development period, my start-up, called donornation.org, went live this month (December 2012)! The response so far has been quite encouraging and I intend to take the company from its current, local San Diego focus, to nationwide, hopefully in the next 2 years. Feel free to check it out and let me know what you think…any feedback and suggestions to help improve the site is always welcome. Being that my day job is running a tech start-up, I don’t have the time to be an active trader…However, being an avid market watcher and investor, I started this blog to maintain a public record of my views on the economy, the markets and my stock picks. My space here has given me the opportunity to share my analysis, good, bad and the ugly, with everyone. It has also allowed me to keep a running scorecard on how effective my investment ideas have been. About a year ago, just after my Options2Wealth blog's public portfolio recorded 10,000%+ return in less than 6 months, I received an offer to write a book based on my blog's accomplishment by one of the most respected literary agents in the United States. This was a totally unintended and unexpected result of my original motivation which was to simply help demystify derivatives (options) and show how just about anyone, armed with the ability to read stock charts, can take advantage of the most powerful wealth building tool legally available to us all. Based on the fact that some of my readers were able to mimic my moves and achieve returns of as much as 4,000%+ tells me that my blog has succeeded in its raison d'être. Finally, I shall be remiss if I did not acknowledge the many public and private comments / messages that I have received, and continue to receive, from my readers here. I want to take this opportunity to let you know that I'm extremely grateful, and humbled, to all those who have taken the time to share your comments, kind thoughts and warm wishes with me...Should you not receive a reply, please do not take my lack of responsiveness as a sign of hubris...Due to my various interests and activities and the fact that I spend a considerable amount of time traveling, my free time is extremely limited and if I have not responded to your message, please accept my sincere apologies... Best of Luck to All! karim pirani
Wall Street Breakfast, Seeking Alpha's flagship daily business news summary, is a one-page summary that gives you a rapid overview of the day's key financial news. It's designed for easy readability on the site or by email (including on mobile devices), and is published before 7:00 AM ET every market day.
Wall Street Breakfast readership of over 900,000 includes many from the investment-banking and fund-management industries.
Sign up here to receive the Wall Street Breakfast in your inbox every business day: http://seekingalpha.com/account/email_preferences
Jim Van Meerten is an advisor to Marketocracy Capital Management and writes on financial subjects here and on Barchart Portfolio Blogs and Seeking Alpha. He earned a BS in Accounting and Business Administration from Berry College; a Juris Doctorate from the Woodrow Wilson School of Law; and attended post-baccalaureate and graduate courses in Business Administration, Quantitative Math, and Education at Florida Atlantic University, Georgia State University and University of North Carolina at Charlotte. In the past he has been an accountant, attorney, adjunct professor in Business Law, Accounting and Internal Auditing, financial advisor, supervisory principal, and compliance officer. He also passed the Georgia CPA Exam, the Certified Internal Auditor Exam, and the FINRA Series 7, 24 and 9/10 exams.He is presently also a contributor on MSN Top Stocks Blog, Motley Fool and is a member of the M100 on Marketocracy, an elete honor chosen by the editors of Marketocracy as being in the top 100 portfolio managers of over 100,000 portfoiios they review. He would enjoy hearing your comments at JimVanMeerten@gmail.com.
I've been a full time trader for about 18 years after selling a business that I wasn't enjoying any more. My true love is the stock market. I'm an aggressive swing trader although I'm trying to keep more position trades and hold em longer. I live in Chicago although I lived most of my life in California.I play the drums and love music and skiing. I miss the Sierras and used to live in Incline Village, Lake Tahoe. So why the heck am I in Chicago?? A woman made me do it. :-)
Option Millionaires was started in February 2008 to provide traders with information about option trading. Led by three career option traders, whose pseudonyms are JimmyBob, UraniumPintoBeans, and Vantillian, they started one of the most popular option trading communities on the web.
Now, Option Millionaires provides a blog, a live chat forum in which we allow our subscribers to mirror our trades, educational classes, and intraday market commentary to its subscribers. Thanks for stopping by and happy trading!
Scott has been trading equities for over 15 years, a majority of which were OTC micro-cap stocks. He started trading high risk stock options over the past 7 years, and has proven winning trades in excess of 15,000%. As one of the Co-Founders of optionmillionaires.com, Scott enjoys sharing his knowledge with other investors through timely blog posts, daily watch lists in the forum, weekly webinars, and helpful commentary in the chatroom.
Curis, Inc. (CRIS) - NasdaqGM rated best investment going forward in Biotech for the remainder of 2014 and certainly for 2015.
Past Results - Achillion Pharmaceuticals, Inc. (ACHN) was issued a best investment rating on April 14, 2014 and it's hoped that on June 16, 2014 that investors locked in profit near the highs. The high that day was $8.05. The best investment rating was issued from the $2.70's area.
Athersys, Inc. (ATHX) - NasdaqCM In 2013 ATHX in the $1.60's area was issued a best investment notice. Followed up with several articles pointing out its potential. It's hoped investors took profit over $4 in early 2014. Today ATHX and its MultiStem is of high risk with one "no efficacy" phase II trial in 2014 reporting. For this reason ATHX is a buy only under $1.60 again today. This will limit downside to some degree if MultiStem fails again to show efficacy in a second phase II trial.
Other past calls were CLDX, ACUR and ALNY.
Paul is a stock investor with an accounting/finance background. He likes to look for value growth stocks and momentum news plays. He is also known as Superman on Twitter @super_trades and his blog is www.super-trades.com (http://www.super-trades.com).
Gary Tanashian is proprietor of NFTRH.com and Biiwii.com. Actionable, hype-free technical, macro economic and sentiment analysis is provided in the premium market report 'Notes From the Rabbit Hole' (http://nftrh.com/nftrh-premium/). Complimentary analysis and commentary is available at the public site (http://nftrh.com), at http://biiwii.com and by email with our free - and spam free - eLetter service (http://nftrh.com/free-eletter/).
I look for a change in sentiment that precedes the change in trend. Moments of "lag" in sentiment can provide superb entry points into special situations at a discount; and obversely, manic enthusiasm can provide an opportunity to go short.
I research the fundamentals, know what I am getting into, and go long or short accordingly. Technical studies of the market are also an active part of my trading. I have invested for 22 years.
10 years of buy-side investment experience.
Disclaimer: Any content on this site is NOT investment, trading, legal, or tax advice, and none of the information available through this website is intended to provide tax, legal, investment or trading advice. Nothing provided through this content whether by the owner or posted by other writers constitutes a solicitation of the purchase or sale of securities/futures. The content on this site is intended for informational purposes only, and should never be used as investment advice. Please do your own research before making any investment decisions.
I am a sell side analyst with 5 years of experience tracking the global equity markets. I have experience tracking the consumer sector for 3 years. My focus is on finding mid-cap stocks that are growth oriented and picking them at attractive valuations.
Leigh Drogen is the Founder and CEO of Estimize. Estimize is an open financial estimates platform which facilitates the aggregation of fundamental estimates from independent, buy-side, and sell-side analysts, along with those of industry experts, private investors and students. By sourcing estimates from a diverse community of individuals, Estimize provides both a more accurate and more representative view of expectations compared to sell side only data.
Leigh started his career as a quant trader at Geller Capital, a White Plains, NY based fund where he ran strategies that looked at earnings acceleration and analyst estimate revision models, as well as price momentum and several sentiment indicators.
Leigh later went on to be the founder of Surfview Capital, a New York based asset management firm that used many of the same strategies as Geller Capital, with a focus on higher beta names on an intermediate term time frame.
His educational background includes focus in economics and international relations, specifically war theory. He is a graduate with honors from Hunter College in New York City.
You can contact Leigh by emailing him at Leigh@estimize.com
Markman Advisors specializes in the strategic analysis of investment opportunities presented by intellectual property—and in particular, patent—litigation activities. We are all USPTO-registered patent attorneys with decades of combined experience in patent litigation, licensing and procurement. After many years practicing at some of the world’s largest and well-known law firms, we established and now run a premier intellectual-property boutique law firm, where we continue to practice patent litigation.
We have litigated numerous high-stakes patent cases in federal district courts throughout the country, as well as at the appellate level before the Federal Circuit. We are also experienced in USPTO proceedings, and have advised clients across a wide swath of technical areas with respect to patent-related matters.
Our base of former and current legal clients is diverse, from technology start-ups to some of the world’s largest and most well-known corporations. Collectively, we have led those clients through numerous Markman hearings, summary judgment motions, trials and appeals – on both the offensive and defensive sides of a case.
Our patent litigation experience, coupled with our knowledge of the market for "patent play" stocks, is the alpha we bring to each patent litigation-driven investment opportunity.
I'm a radiologist by trade, but the goal is to leverage that medical knowledge as a competitive advantage in the markets. I aim to include all of the following in my analyses to ensure high quality: 1) quantitative estimates; 2) new information or inferences that are not already disseminated throughout the market; and 3) hypotheses that are testable, i.e. can be proved right or wrong. I have a serious allergy to question marks and will never, ever include one in an article title.
My dream is to co-found a biotech and bring a cure from the lab to the bedside. In the meantime, saving lives in clinical practice is a perfectly acceptable alternative.
Please note that all opinions I express on this website reflect my personal beliefs only and are completely independent of my current or past employers and/or affiliated institutions.
I am an independent equity research analyst and consultant. I focus on finding small-cap biotech stocks where I believe there is favorable risk / reward because of misinformation, lack of information, or a potential fundamental turnaround. I provide detail analysis for investors and investor relations companies. I also provide due diligence and advisory services to companies. Some names I write on I invest in personally and will disclose my position. Names that have hired me to provide due diligence or advisory services I will disclose a business relationship. I previously worked for Zacks Investment Research from 2003 to 2015 as a Senior Biotechnology Analyst. Prior to Zacks, I spent 1999 to 2002 managing money with Eastover Capital in Charlotte, NC where I focused on large-cap equities, specializing in healthcare, energy, and technology. Prior to joining Eastover, I worked as a research scientist for TechLab, Inc., a biotechnology company focused on developing diagnostic kits and vaccines for infectious diseases, between 1995 and 1998. I also spent a year working at the Fralin Biotechnology Center, and a year working for a cancer researcher while at Virginia Tech. I have a B.S. in Biochemistry from Virginia Tech, with a B.A in Chemistry and a minor in Math. I have a M.B.A. in Finance, with a concentration in Securities Analysis, from Wake Forest University. I hold the Chartered Financial Analyst (CFA) designation.
An experienced research and advisory team of Traders and Forecasters have combined to offer free services and alerts at StockReversals.com, A free growth stock profile, research and alert service with benefits. Go to the website to subscribe for free. We also offer StockReversalsPremium.com which offers a combination of long term growth stock profiles with massive upside potential, plus swing position trading (days to 8 weeks holding).
Seeking Alpha Certified and Frequent Contributor to numerous financial websites. We specialize in behavioral analysis as it applies to market patterns and reversal trends. These trends happen over short term, intermediate, and long term time frames. We help our free subscribers with Business Disruptor growth stocks that crush the market. Sample picks include FB, YY, DATA, INVN, SPCB, MOBI, CUR and many more. In 6 months we had 6 doubles, 1 triple, and 16 of 19 companies up 30-50% or more.
Our work centers around a combination of Elliott Wave Theory, Technical Analysis, Human Behaviors, Sentiment, and Business Disruption analysis.
We have advisory clients from around the world. South Korea, Australia, Canada, Sweden, Germany, The Netherlands and of course the U.S.
We give away our service for free because of the laws of nature which we have on our website:
“The possession of knowledge, unless accompanied by the manifestation and expression in sharing is a vain and foolish thing. The Law of Use is universal, and he who violates it suffers by reason of his conflict with natural forces.”
Join us today at stockreversals.com and sign up for free.
I'm managing editor for SA PRO. I work primarily on our PRO product, though also in support of our marketplace product and in a few other areas on the site. I'm always happy to hear from readers and contributors, whether to help with questions, hear your feedback, or learn how you're using the site. I've been working at SA since September 2012.
I've been investing for 6 years. I used to write articles for Seeking Alpha before becoming an editor (while I'm proud of the work I did, it probably would not have been up to our PRO standards, which is a good thing). I am probably one of SA's most frequent users, and have learned an immense amount from contributors, readers, and SA employees.
Beyond the market, I like reading, travel, writing, playing/writing/listening to music, and learning languages. Probably most relevant to ask me about SA, but you're welcome to get in touch on anything else as well.
I am the VP of Monetization at Harvest (www.hvst.com). My role here is to ensure that Harvest is maximizing its monetization opportunities while maintaining the highest level of experience for our users, and advertisers.